Gunderson Dettmer Stough Villeneuve Franklin & Hachigian

Startups & Emerging Companies Department

USA - Nationwide
Current View:

This content is provided by Chambers. Learn more about our methodology

What the team is known for Maintains a dedicated emerging companies practice, with the ability to advise investors and early-stage tech companies on a diverse spectrum of matters, including international investments. Also provides guidance on complementary areas of law, such as employee benefits and executive compensation, IP and tax. Regularly advises clients who operate in the media, software and pharmaceutical sectors.

Strengths"They have a great understanding of our business and how it ties into the law," says a source, praising the firm's "ability to delve into the details" and "their encyclopedic knowledge of the issues at hand."

Another interviewee adds: "I continue to be impressed with Gunderson - they provide excellent client service."

Work highlights Advised cybersecurity company Duo Security during its $2.35 billion acquisition by Cisco.

Notable practitioners

Bob Gunderson
maintains his longstanding and renowned practice representing high-growth companies and investors in a range of financial transactions, alongside acting as chairman of the firm.

David  Gammell
recently moved to the firm's Boston office and represents startup companies throughout their lifecycle. He also acts on behalf of venture capital funds in financing transactions.

Ivan Gaviria
's practice revolves around the technology sector, largely acting for company-side clients. His work includes acting on financing rounds and M&A.

Jay Hachigian
's practice sees him regularly handling financings for life sciences and technology companies. His work with venture capital sponsors includes both investments and fund formation.

Ken McVay
is hailed by peers as "terrific; a wonderful lawyer." He acts on behalf of both emerging companies and venture funds in the technology industry.

Scott Dettmer
represents businesses from the technology and life sciences sectors in financing transactions. His client base also extends to a number of growth equity funds.